uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
Multicenter Reproducibility of F-18-Fluciclatide PET Imaging in Subjects with Solid Tumors
Univ London Imperial Coll Sci Technol & Med, Hammersmith Hosp, Fac Med, Dept Expt Med, London W12 0NN, England..
HCG, PETCT, Bangalore, Karnataka, India.;HCG, Cyclotron Dept, Bangalore, Karnataka, India..
Asan Med Ctr, Dept Nucl Med, Seoul, South Korea..
Manipal Hosp, Dept Nucl Med, Bangalore, Karnataka, India.;Manipal Hosp, PET CT Div, Bangalore, Karnataka, India..
Show others and affiliations
2015 (English)In: Journal of Nuclear Medicine, ISSN 0161-5505, E-ISSN 1535-5667, Vol. 56, no 12, 1855-1861 p.Article in journal (Refereed) PublishedText
Abstract [en]

Integrins are upregulated on both tumor cells and associated vasculature, where they play an important role in angiogenesis and metastasis. Fluciclatide is an arginine-glycine-aspartic acid peptide with high affinity for alpha(v)beta(3)/alpha(v)beta(5) integrin, which can be radio-labeled for PET imaging of angiogenesis. Thus, F-18-fluciclatide is a potential biomarker of therapeutic response to antiangiogenic inhibitors. The aim of this study was to evaluate the reproducibility of F-18-fluciclatide in multiple solid-tumor types. Methods: Thirty-nine patients underwent PET/CT scanning at 40, 65, and 90 min after injection of F-18-fluciclatide (maximum, 370 MBq) on 2 separate days (2-9 d apart). Patients did not receive any therapy between PET/CT scans. F-18-fluciclatide images were reported and quantitative measures of uptake were extracted using the PERCIST methodology. Intrasubject reproducibility of PET uptake in all measurable lesions was evaluated by calculating relative differences in SUV between PET scans for each lesion during the 2 imaging sessions. Results: Thirty-nine measurable lesions were detected in 26 patients. Lesion uptake correlated strongly across imaging sessions (r = 0.92, P < 0.05, at 40 min; r = 0.94, P < 0.05, at 65 min; r = 0.94, P, 0.05, at 90 min) with a mean relative difference and SD of the relative difference of 0.006 +/- 0.18 at 40 min, 0.003 +/- 0.19 at 65 min, and 0.025 +/- 0.20 at 90 min. This reflects 95% limits of repeatability of 35%-39% for the difference between the 2 SUV measurements or a variability of 18%-20% in agreement from that observed in well-calibrated multicenter F-18-FDG studies. Conclusion: The test-retest reproducibility of F-18-fluciclatide across multiple tumor types has been measured and shown to be acceptable. This is an important step in the development of this in vivo biomarker to identify and quantify response to antiangiogenic therapy in cancer patients.

Place, publisher, year, edition, pages
2015. Vol. 56, no 12, 1855-1861 p.
Keyword [en]
reproducibility, F-18-fluciclatide, cancer, angiogenesis
National Category
Cancer and Oncology Radiology, Nuclear Medicine and Medical Imaging
URN: urn:nbn:se:uu:diva-270948DOI: 10.2967/jnumed.115.158253ISI: 000365724800010PubMedID: 26383153OAI: oai:DiVA.org:uu-270948DiVA: diva2:890890
Available from: 2016-01-05 Created: 2016-01-05 Last updated: 2016-01-21Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Lindman, Henrik
By organisation
Experimental and Clinical Oncology
In the same journal
Journal of Nuclear Medicine
Cancer and OncologyRadiology, Nuclear Medicine and Medical Imaging

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 45 hits
ReferencesLink to record
Permanent link

Direct link